Markets

MacroGenics Doses First Patient In Phase 1 Study Of MGC030, Antibody-Drug Conjugate Directed Against Undisclosed Target, In Patients With Advanced Solid Tumors

Oct 15, 2026 · 04:06 PM ET· updated 54m ago

MacroGenics, Inc. (NASDAQ:MGNX), a clinical-stage biopharmaceutical company focused on developing innovative antibody-based therapeutics for the treatment of cancer, today announced that the first patient has been dosed

Why It Matters

MacroGenics started testing a new cancer medicine in patients. When a company moves a new drug into human testing, watch if patients improve and if side effects stay manageable.

This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.

Tickers in Play

MGNX3.32

+0.01 (+0.30%)

Last session drawn · prints held ~15 minutes · licensed exchange data

Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.

Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.